semaglutide essence trial Phase 3 trial: in metabolic dysfunction-associated steatohepatitis Upcoming GLP-1 RAs for NASH:

Addressing these issues requires a concerted effort from researchers, clinicians, regulators, and ethicists to develop personalized treatment protocols, establish clear and consistent regulatory guidelines, and create robust ethical frameworks

Himo, F

These factors can work together to increase the chance of drug-related liver issues, including jaundice

The GLP-1R is expressed in various tissues, including but not limited to pancreatic -cells, various cell types of the gastrointestinal tract, neurons throughout the peripheral and central nervous system (CNS), the kidney, the vasculature, and the heart [8,9,10]

For the continuous variables, the mean difference and standard deviation were extracted from the intervention and placebo group respectively, using the WMD to estimate the treatment effect of the randomized controlled trials

Outcomes are influenced by starting BMI, metabolic health, diet, physical activity, and strict adherence to the prescribed titration schedule